Amgen (AMGN) Blincyto Receives EU Label Expansion for Consolidation Therapy in Adult Acute Lymphoblastic Leukemia
Full Expansion of the BiTE Platform Leader's Indications in Europe
Amgen's (AMGN) CD19·CD3-targeted bispecific T-cell engager (BiTE) Blincyto (blinatumomab) has received marketing authorization label expansion from the European Medicines Agency (EMA) for consolidation therapy in adult newly diagnosed Philadelphia chromosome-negative (Ph-) B-cell precursor acute lymphoblastic leukemia (ALL). This is a breakthrough regulatory achievement that officially extends the treatment horizon from the existing relapsed/refractory (R/R) and minimal residual disease (MRD)-positive settings to first-line therapy for early-stage disease. This lays the groundwork for a clinical turning point, enabling the early preemptive eradication of leukemia cells to increase long-term cure rates and minimize the risk of recurrence. Adult leukemia patients in Europe now have access to a powerful targeted immunotherapy option alongside standard chemotherapy from the outset.
Overwhelming Survival Benefit Demonstrated in Pivotal Phase 3 E1910 Trial
The core evidence for this European approval is the data from the large-scale multicenter randomized Phase 3 'ECOG-ACRIN E1910' trial, conducted with support from the National Cancer Institute (NCI). Analysis of the cohort of adult patients who achieved complete remission after induction chemotherapy demonstrated that the group receiving blinatumomab in combination with standard consolidation chemotherapy achieved a 3-year overall survival (OS) rate of 85%, showing remarkable survival improvement compared to the chemotherapy-alone group (68%). In particular, it drastically reduced the risk of death by 59% with a hazard ratio (HR) of 0.41, proving the superior efficacy of immunotherapy while reducing the toxicity burden of cytotoxic anticancer drugs in the first-line treatment setting. This served as decisive scientific evidence to fundamentally change adult acute leukemia treatment guidelines.
Leap to Blockbuster Status and Expansion of Acute Leukemia Market Dominance
The global acute lymphoblastic leukemia (ALL) treatment market size reached approximately $2.4 billion to $3.7 billion as of 2023 and continues to show steady growth at an annual average of 4-7%. Blincyto's annual global revenue surged 41% year-on-year, from $861 million in 2023 to $1.216 billion in 2024, establishing itself as a true mega-blockbuster product. This addition of the first-line consolidation therapy indication in Europe can simultaneously drive an extension of treatment cycles per patient and expand the potential prescription population. Accordingly, it is expected to strongly drive top-line growth in Amgen's hematologic malignancy sector along with increased market share in the European market.
Differentiated Convenience Compared to CAR-T and ADC, with Outlook for Reimbursement Approval
In the blood cancer field, intense competition is currently underway between CAR-T cell therapies such as Novartis's Kymriah and Pfizer's antibody-drug conjugate (ADC) Besponsa. However, while CAR-T faces burdens such as delays in patient-specific manufacturing (vein-to-vein time), high treatment costs, and management of severe cytokine release syndrome (CRS), Blincyto offers the convenience of immediate administration in an off-the-shelf format. Leveraging this EU approval, Amgen plans to quickly enter price setting and insurance reimbursement negotiations with health authorities in major member states such as Germany, France, and Italy. The economic evaluation factors, such as the reduction in recurrence rates through early treatment and the reduction in demand for high-cost hematopoietic stem cell transplantation (HSCT), are expected to act very favorably in the reimbursement reviews of various European countries.
As Amgen (AMGN) receives approval for Blincyto as an adult first-line consolidation therapy during its marketed stage, short-term revenue growth for the drug—which achieved $1.216 billion in annual sales in 2024 (YoY +41%) in the global acute lymphoblastic leukemia (ALL) market valued at approximately $2.4 billion to $3.7 billion in 2023—will accelerate further. The data demonstrating an 85% 3-year overall survival rate and a 59% reduction in the risk of death (HR 0.41) from the Phase 3 trial (ECOG-ACRIN E1910) serves as a powerful weapon for securing first-line treatment precedence compared to Pfizer's (PFE) Besponsa or Novartis's (NVS) Kymriah. From the perspective of researchers and the pharmaceutical industry, it is significant to establish a clinical standard that replaces or complements cytotoxic chemotherapy by expanding the indication of the BiTE platform, which was previously limited to MRD-positive cases, to early treatment. In the medium to long term, it is expected to facilitate insurance reimbursement listings in major European countries by preventing recurrence and reducing the demand for high-cost hematopoietic stem cell transplantation, further solidifying the profitability of Amgen's oncology pipeline.
Source: EMA (ema)